ScoutQuest21 Nov 2026
Lords Mark Industries501261Periodic business update

Lord's Mark Industries investor summit transcript: Q2/H1 update and 18-month launch roadmap

Management says Q2 growth came primarily from the medical devices division after 26 additional IVD device manufacturing licences were received.

By ScoutQuest · · 1 min read

85%Stake acquired in Renalyx
Stake acquired in Renalyx: almost 85%.
Additional IVD manufacturing licences
26 additional IVD medical devices manufacturing licences
Renewable energy order pipeline
3,000-plus crore
Renalyx stake
almost 85% stake in Renalyx
Period
Q2 and H1 FY27; 19th November, 2026
Positioning
Describes itself as a diversified conglomerate running two platforms — IVD/MedTech (dialysis, genomics, diagnostics) and renewable energy — with 35-plus products across 15-plus states

📈 Management said the growth seen in the second quarter came primarily from the medical devices division, helped by 26 additional IVD medical devices manufacturing licences that widened the product range; no revenue, EBITDA or profit figures are printed on these pages.

📌 The company puts its renewable energy order pipeline at 3,000-plus crore, backed by a Maha PSU and government relationships and described as confirmed orders for the next couple of years, alongside 35-plus products, 15-plus states, 700-plus distributors and 200 and more enterprise clients.

🔬 Management states that commercial shipments of the Renalyx RXT 21 dialysis machine begin in December, with sickle cell screening and UK sales from January 2027, CAR-T clinical trials from February 2027 and US sales from March 2027 subject to US FDA approval.

🏭 It says a third IVD manufacturing plant is targeted by March 2028 and advanced CAR-T treatment centres by June 2028, supported by CDSCO approvals, CE certification, UK MHRA listing, licences from IIT Bombay and BARC, GMP plants and an almost 85% stake in Renalyx.

More numbers
  • Renewable energy order pipeline3,000-plus crore
  • Registered trademarks139
  • IVD distributors700-plus
  • Products in portfolio35-plus
  • States of presence15-plus
  • Stake acquired in Renalyxalmost 85%
  • Additional IVD medical devices manufacturing licences received26 additional IVD medical devices manufacturing licenses
  • Cancer types addressed by CAR-T therapy18 types of cancers
  • Order book3,000-plus crore
Source: BSE · 21 Nov 2026

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev